لیناگلیپتین (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "لیناگلیپتین" in Persian language version.

refsWebsite

Global rank Persian rank

4^th place

5^th place

2boehringer-ingelheim.com

low place

low place

2web.archive.org

1^st place

1^st place

447^th place

382^nd place

low place

low place

68^th place

179^th place

6^th place

9^th place

2^nd place

2^nd place

1semanticscholar.org

11^th place

52^nd place

399^th place

104^th place

1genengnews.com

low place

low place

low place

low place

archive.org

Neumiller JJ (March 2012). "Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus". The Annals of Pharmacotherapy. 46 (3): 358–67. doi:10.1345/aph.1Q522. PMID 22318932. S2CID 207264493.

boehringer-ingelheim.com

docs.boehringer-ingelheim.com

"Tradjenta (linagliptin) Tablets. Full Prescribing Information" (PDF). Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA. Retrieved 10 November 2016.
https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Tradjenta/Tradjenta.pdf?

doi.org

Neumiller JJ (March 2012). "Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus". The Annals of Pharmacotherapy. 46 (3): 358–67. doi:10.1345/aph.1Q522. PMID 22318932. S2CID 207264493.

drugbank.com

go.drugbank.com

"Linagliptin". go.drugbank.com (به انگلیسی). Retrieved 2023-12-31.

drugs.com

"Linagliptin Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 6 April 2019.

europa.eu

ema.europa.eu

"Trajenta EPAR". آژانس دارویی اروپا (EMA).

fda.gov

"DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain". U.S. Food and Drug Administration (FDA). 2015-08-28. Retrieved 1 September 2015.
"DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain". U.S. Food and Drug Administration (FDA). 28 August 2015. Archived from the original on 13 December 2019. Retrieved 1 September 2015.

genengnews.com

"Four Phase III Trials Confirm Benefits of BI's Oral, Once-Daily Type 2 Diabetes Therapy". Genetic Engineering & Biotechnology News. 28 June 2010. Archived from the original on 31 اكتبر 2018. Retrieved 13 August 2021. {{cite news}}: Check date values in: |archive-date= (help)

nih.gov

ncbi.nlm.nih.gov

S. Blech, E. Ludwig-Schwellinger, E. U. Gräfe-Mody, B. Withopf, K. Wagner: The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. In: Drug Metab. Dispos. Band 38, Nr. 4, April 2010, S. 667–678, doi:10.1124/dmd.109.031476, PMID 20086031.
L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayyon, F. Himmelsbach, M. Mark: (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. In: J. Pharmacol. Exp. Ther. Band 325, Nr. 1, April 2008, S. 175–182, doi:10.1124/jpet.107.135723, PMID 18223196.

pubmed.ncbi.nlm.nih.gov

Neumiller JJ (March 2012). "Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus". The Annals of Pharmacotherapy. 46 (3): 358–67. doi:10.1345/aph.1Q522. PMID 22318932. S2CID 207264493.

pbs.gov.au

"Pharmaceutical Benefits Scheme (PBS) | Linagliptin, tablet, 5 mg, Trajenta® - July 2012".

semanticscholar.org

api.semanticscholar.org

Neumiller JJ (March 2012). "Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus". The Annals of Pharmacotherapy. 46 (3): 358–67. doi:10.1345/aph.1Q522. PMID 22318932. S2CID 207264493.

web.archive.org

"Four Phase III Trials Confirm Benefits of BI's Oral, Once-Daily Type 2 Diabetes Therapy". Genetic Engineering & Biotechnology News. 28 June 2010. Archived from the original on 31 اكتبر 2018. Retrieved 13 August 2021. {{cite news}}: Check date values in: |archive-date= (help)
"DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain". U.S. Food and Drug Administration (FDA). 28 August 2015. Archived from the original on 13 December 2019. Retrieved 1 September 2015.